OVERVIEW

RME Hot Seat: Weighing the Clinical Evidence on Treatment Strategies for Myeloma is organized by RedMedEd.

Release date: 4/16/2021
Expiration date: 4/16/2022

Target Audience:
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with MM.

Overview:
This RME Hot Seat provides a virtual Q&A with a panel of multiple myeloma (MM) experts who field a range of questions on MM patient care, covering such topics as the use of minimal residual disease (MRD)–driven maintenance approaches, immunotherapy, the use of belantamab mafodotin, cytogenetic risk status, and the value of three-drug and four-drug regimens.

Learning Objectives:
Upon completion of this activity, participants should be better able to:
• Evaluate emerging data regarding the approach to maintenance therapy based on MRD status
• Describe the options available to patients who have relapsed from or are resistant to multiple prior therapies
• Incorporate the use of novel agent/monoclonal antibody–based regimens for newly diagnosed or relapsed/refractory MM patients based on currently available evidence